title: PURLs: Need an add-on to metformin? Consider this.
abstract: Sulfonylureas have been the preferred add-on therapy to metformin for T2DM, but a study finds that DPP-4s have lower risks of death, CV events, and hypoglycemia.
authors.affiliation: Saint Joseph Health System Family Medicine Residency, Mishawaka, IN, USA.
authors.forename: David
authors.initials: D
authors.lastname: Wyncott
authors.affiliation: University of Colorado Family Medicine Residency, Denver, CO, USA.
authors.forename: Corey
authors.initials: C
authors.lastname: Lyon
authors.affiliation: Department of Family Medicine, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Anne
authors.initials: A
authors.lastname: Mounsey
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D008687:Metformin